Benefits of Natural Compounds in Diabetes Complications by Prevention and Reversing Protein Glycation and Protecting Cells against Oxidative Stress

Madhurima Chatterjee¹, Anna Goc¹, Aleksandra Niedzwiecki^1, and Matthias Rath¹

¹Dr. Rath Research Institute, 5941 Optical Court, San Jose, CA 95138, USA

Cite this paper:
Madhurima Chatterjee, Anna Goc, Aleksandra Niedzwiecki and Matthias Rath. Benefits of Natural Compounds in Diabetes Complications by Prevention and Reversing Protein Glycation and Protecting Cells against Oxidative Stress. American Journal of Food and Nutrition. 2024; 12(3):87-93. doi: 10.12691/ajfn-12-3-2

Abstract

Background: Diabetes is a global health crisis. Chronic hyperglycemia leads to the formation of glycated proteins known as Advanced Glycated End Products (AGEs) which damage multiple organs resulting in diabetes-related retinopathy, atherosclerosis, neuropathy and other pathologies. Therefore, prevention and reversal of protein glycation is an important aspect in diabetes management, especially involving natural, non-toxic approaches. Methods and Results: We tested the efficacy of natural compounds, including Krebs cycle mediators and amino acids in different aspects of diabetes. Firstly, we demonstrated that these compounds work individually and synergistically to prevent glycation of bovine serum albumin caused by glucose and fructose. Secondly, our study showed that the test compounds reverse glycation of L-lysine by converting Nε-(1-Carboxymethyl)-L-lysine to L-lysine in vitro, implying that natural removal of AGEs is possible. We also demonstrated that combinations of natural compounds can address important aspects of diabetes metabolism, such as impaired mitochondrial bioenergetics and cellular damage by oxidative stress. Conclusion: Our data show that the combination of natural compounds stimulates mitochondrial activity and mitobiogenesis in skeletal muscle cells, which are impaired in diabetes and linked to the development of diabetic cardiomyopathy. In addition, these natural compounds protect microglial cells from oxidative stress –a common hallmark of hyperglycemia implicated in neuropathy, vascular systems damage and other pathologies. Our data demonstrate that a combination of selected natural compounds has superior biological efficacy compared to its individual components in important metabolic aspects of diabetes and should be further evaluated as a non-toxic alternative in diabetes treatment and/or management.

Keywords:
diabetes Advanced Glycation End products (AGEs) micronutrients

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, et al. “Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.” Neurobiol Aging, vol. 32(5). 763-777. 2011.
[2]	Simm A, Wagner J, Gursinsky T, Nass N, Friedrich I, Schinzel R, et al. “Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?” Exp Gerontol, vol. 42(7). 668-675. 2007.
[3]	Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. “Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.” Prostate, vol. 64(1). 92-100. 2005.
[4]	Garg D, Grazi R, Lambert-Messerlian GM, Merhi Z. “Correlation between follicular fluid levels of sRAGE and vitamin D in women with PCOS.” J Assist Reprod Genet, vol. 34(11). 1507-1513. 2017.
[5]	Delgado-Andrade C.” Carboxymethyl-lysine: thirty years of investigation in the field of AGE formation.” Food Funct, vol. 7(1). 46-57. 2016.
[6]	Brownlee M. “Advanced protein glycosylation in diabetes and aging.” Annu Rev Med., vol. 46. 223-234. 1995.
[7]	Tanaka S, Avigad G, Brodsky B, Eikenberry EF. “Glycation induces expansion of the molecular packing of collagen.” J Mol Biol., vol. 203(2). 495-505. 1988.
[8]	Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. “Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin.” J Biol Chem., vol. 269(51), 32299-32305. 1994.
[9]	Ahmed MU, Thorpe SR, Baynes JW. “Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein.” J Biol Chem., vol. 261(11). 4889-4894. 1986.
[10]	Roncero-Ramos I, Niquet-Léridon C, Strauch C, Monnier VM, Tessier FJ, Navarro MP, et al. “An advanced glycation end product (AGE)-rich diet promotes Nε-carboxymethyl-lysine accumulation in the cardiac tissue and tendons of rats.” J Agric Food Chem., vol. 62(25):6001-6006. 2014.
[11]	Imanaga Y, Sakata N, Takebayashi S, Matsunaga A, Sasaki J, Arakawa K, et al. In vivo and in vitro evidence for the glycoxidation of low-density lipoprotein in human atherosclerotic plaques. Atherosclerosis., vol. 150(2). 343-355. 2000
[12]	Mastrocola R, Nigro D, Cento AS, Chiazza F, Collino M, Aragno M. “High-fructose intake as risk factor for neurodegeneration: Key role for carboxy methyllysine accumulation in mice hippocampal neurons.” Neurobiol Dis., vol. 89. 65-75.2016.
[13]	Semba RD, Fink JC, Sun K, Bandinelli S, Guralnik JM, Ferrucci L. “Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults.” Eur J Nutr., vol. 48(1). 38-44. 2009.
[14]	Schmidt AM, Yan SD, Wautier JL, Stern D. “Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.” Circ Res., vol. 84(5). 489-497. 1999.
[15]	Xue J, Rai V, Singer D, Chabierski S, Xie J, Reverdatto S, et al. “Advanced glycation end product recognition by the receptor for AGEs.” Structure. vol. 19(5):722-32. 2011.
[16]	Kim NY, Goddard TN, Sohn S, Spiegel DA, Crawford JM. “Biocatalytic Reversal of Advanced Glycation End Product Modification.” Chembiochem., vol. 20(18). 2402-2410. 2019.
[17]	Marques S, Trevisan T, Maia C, Breuer A, Owen RW. “Improved Methods for the Rapid Formation and Prevention of Advanced Glycation End Products (AGEs) In Vitro by Coupling to the Hypoxanthine/Xanthine Oxidase Assay System.” Biomedicines., vol. 6(3). 88. 2018.
[18]	Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, et al. “SDHA is a tumor suppressor gene causing paraganglioma.” Hum Mol Genet. vol. 19(15). 3011-3020. 2010.
[19]	Giacco F, Brownlee M. “Oxidative stress and diabetic complications.” Circ Res., vol. 107(9). 1058-70. 2010.
[20]	Bonnard C, Durand A, Peyrol S, Chanseaume E, Chauvin MA, Morio B, et al. “Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice.”’ J Clin Invest., vol. 118(2). 789-800. 2008.
[21]	Gonzalez AM, Trexler ET. “Effects of Citrulline Supplementation on Exercise Performance in Humans: A Review of the Current Literature.” J Strength Cond Res., vol. 34(5).1480-1495. 2020.
[22]	Arribas-López E, Zand N, Ojo O, Snowden MJ, Kochhar T. “The Effect of Amino Acids on Wound Healing: A Systematic Review and Meta-Analysis on Arginine and Glutamine.” Nutrients. vol. 13(8). 2498. 2021.
[23]	Chilukuri H., Kulkarni M.J., Fernandes M. “Revisiting amino acids and peptides as anti-glycation agents.” Med. Chem. Commun., vol. 9. 614–624. 2018.
[24]	Zhou Z, Tang Y, Jin X, Chen C, Lu Y, Liu L, et al. “Metformin Inhibits Advanced Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly through AMPK Activation and RAGE/NFκB Pathway Suppression.” J Diabetes Res.4847812. 2016.
[25]	Abdullah KM, Qais FA, Ahmad I, Hasan H, Naseem I. “Study of pyridoxamine against glycation and reactive oxygen species production in human serum albumin as model protein: An in vitro & ex vivo approach.” Int J Biol Macromol., vol. 120(Pt B). 1734-1743.2018.
[26]	Pashikanti S, de Alba DR, Boissonneault GA, Cervantes-Laurean D. “Rutin metabolites: novel inhibitors of nonoxidative advanced glycation end products.” Free Radic Biol Med., vol. 48(5). 656-663. 2010.
[27]	Divisova S, Vlckova E, Srotova I, Kincova S, Skorna M, Dusek L, et al. “Intraepidermal nerve-fibre density as a biomarker of the course of neuropathy in patients with Type 2 diabetes mellitus.” Diabet Med., vol. 33(5). 650-654. 2016.
[28]	Lorenzo-Almorós A, Tuñón J, Orejas M, Cortés M, Egido J, Lorenzo Ó. “Diagnostic approaches for diabetic cardiomyopathy.” Cardiovascu diabetol., vol. 16(1). 28. 2017.